Integrating Transcriptome Reprogramming Into Cardiac Plasticity Regulatory Mechanisms

点击翻译按钮获取中文摘要

Project Abstract Programmed terminal differentiation of cardiac myocytes is vital for reorganizing the heart's structure and function to meet basic physiologic demands. Many of these differentiation mechanisms are redeployed after ischemic injury or in the context of heart disease. While terminal differentiation is indispensable for basic cardiac function this fate change is associated with the nearly complete cessation of myocyte proliferation, which underlies one of the major barriers in the treatment of ischemic heart disease- the lack of effective therapeutic strategies to remuscularize the fibrotic heart. Many differentiation mechanisms are redeployed after injury, but it's unclear whether the response is adaptive or pathologic, thus understanding how the flow of genetic information establishes and maintains myocyte differentiation improves our current knowledge of basic cardiac physiology and provides insights into cardiac regeneration and disease. Much of our knowledge about terminal differentiation has come from investigating gene regulatory mechanisms at the level of DNA and epigenetics with little attention paid to post-transcriptional control of the cardiac transcriptome. Here we are hijacking the function of a highly conserved RNA-binding protein muscle blind like-1 (MBNL1) to understand how transcriptional reprogramming of myocyte terminal differentiation impacts post natal development and post-infarct regenerative and pathologic remodeling. Specifically, this application will use an array of gain and loss of function mouse models that permit cardiac myocyte specific temporal dosing of MBNL1 to reprogram the heart's transcriptome to achieve the following aims: (1) determine the role of MBNL1-dependent transcriptome reprogramming in establishing and maintaining cardiac myocyte differentiation, (2) define the role of MBNL1-dependent transcriptome reprogramming in post-infarct regenerative and pathologic myocyte remodeling, and (3) determine context dependent regulatory mechanisms underlying MBNL1-dependent transcriptome reprogramming. Data from these aims will identify potential mechanisms by which transcriptional reprogramming can be used to control either endogenous or stem-cell derived myocyte fate as a novel therapeutic strategy for cardiac remodeling and regeneration.